ArticlePathology research international2012
Development of Immunopathogenesis Strategies to Treat Behçet's Disease.
Article in Pathology research international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04105439 (Relation Between Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .), which is not on this map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Relation Between Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Interventions for the management of oral ulcers in Behçet's disease.The Cochrane database of systematic reviews · 2014Pooled it
- Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behçet's Syndrome.The Cochrane database of systematic reviews · 2014Pooled it
- Acute coronary syndrome in Behcet's syndrome: A systematic review.European journal of rheumatology · 2021Review
- Dysregulation of glycerophospholipid metabolism during Behçet's disease contributes to a pro-inflammatory phenotype of circulating monocytes.Journal of translational autoimmunity · 2020Article
- Evalution of Renal Involvement in Patients with Behçet Disease: Need to be Aware About Potential Hypertension in Long Term Follow Up?Polish journal of radiology · 2016Article
- Morbus Behçet - a rare disease in Central Europe.Archives of medical science : AMS · 2015Article
- Thrombosis in vasculitis: from pathogenesis to treatment.Thrombosis journal · 2015Article
- Behçet's disease leaves the silk road.Postepy dermatologii i alergologii · 2014Article
- Behçet's syndrome pathophysiology and potential therapeutic targets.Internal and emergency medicine · 2014Review
- Improved clinical control of a challenging case of Behçet's disease with rituximab therapy.Clinical rheumatology · 2014Article
- New approaches in immunotherapy of behçet disease.Advanced pharmaceutical bulletin · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet disease is a chronic relapsing vasculitis with unclear etiology and immunopathogenesis. Antigenic stimuli, antigen presenting cells, T cells, monocyte, and neutrophil and endothelial cells are major parts of the pathology of the disease. Understanding of the new pathogenic mechanisms based on molecular structure of the disease helps us in improving the novel therapeutic modalities. These drugs target specific and nonspecific inhibition of the immun system. These therapies include biologic agents, new topical and systemic immunosuppressants, tolerizing agents, and immunoablation. Novel treatment will be promising to treat the especially recalcitrant cases to conventional therapy. In this paper, new aspect of the immunopathogenesis of Behçet's diseases and novel treatment modalities will be discussed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.